Theratechnologies Inc T.TH

Any analyst downgrades

[Trogarzon]

For what they're worth.

[SPCEO1]

Cantor stays at a Buy with a $9 price target Cannaccord stays at a Hold and $2 price target NBF stays at a Hold but lowers the price target to C$1.75 from C$2.25 Research Captial stays at a Buy but lowers the price target to $3.50 from $4.50 Leede Jones stays at Specualtive Buy but lowers the price target to C$2 from C$3.75 Jones Trading remains suspiciosly MIA. 

[Trogarzon]

Ok thanks... next milestone July 28 to see what happens with Marathon, then august for share issue and consolidation for Nasdaq.. and then what we wait for F8 filing in September and then mid 2024 for cancer data... and then the AGM.. lol. When was the last good surprise we got.. 2018... any deal Paul.. too late for that and too early for that now.  Why should anyone buy a single share of

[SPCEO1]

Paul was pretty clear that they wil be more transparent with the restarted trial/ If there is good ionfo coming out of the first few patients, I think we will hear about it in the Fall. IF we don't hear about it, then there is likely cause for some concern.

[LouisW]

I dont think so. Paul clearly said that  "We plan to keep the market well informed of our activities and intend to announce trial recruitment updates throughout the remainder of the year. At the pace we're going, we believe that by the end of the first half of fiscal '24, we will be able to announce preliminary safety and efficacy data." I believe they would update the

[SPCEO1]

THTX is in need of a few wins, don't you think? So, if THTX is fortunate to see good early results in the restarted trial, the urge to share those will no doubt be quite strong. Given they are breaching liquidity covenants on their loan, the incentives are in place to share any good results. Indeed these are really, really strong incentives as this could help them raise money at more

[SPCEO1]

There was a typo - it should have read "There is an immediate need for $10 million" not 110 million. 

[Mannequin]

I had an accountant at work who slipped a zero like that. He was fired. 

[LouisW]

I agree TH needs a very good news desperately. But I am not quite sure that the news is related to oncology. What impressed me was that Paul said "we are very active on the business development front, we have a very real opportunity to further accelerate our growth through bolt-on accretive acquisitions of existing brands, which can be quickly added into our commercial platform." 

[SPCEO1]

Could be. I have to admit my ears are a bit numb when it comes to THTX talking about bolt on acquisitions of product as they have talked about it for a very long time without delivering anything. Also, it seems improbable they wpould be able to pull off a deal that would actually generate good returns. But maybe they have finally come up with something. One reason for my skepticism surrounding

[PWIB123]

In my opinion, this is there way of trying to pump the stock price or keep everyone waiting to sell even though they seem unwilling to do it with realtime data around actual possibilities.  They've stated similar hints at NASH partnerships, Chinese involvement, and hopeful trial outcomes, none of which have come to fruition...yet.  They have a history of hinting at things that never

[Garp1]

For someone who kept the BOD in place with the discussion you had with them, your answer is pretty foggy, non committal and again kicks the can even further to an unknown date.